<DOC>
	<DOCNO>NCT00031083</DOCNO>
	<brief_summary>In study investigational replication-defective , recombinant adenovirus express interferon-beta gene ( BG00001 ) directly inject tumor , patient recurrent Grade III Grade IV Gliomas , order deliver hIFN-beta gene . The purpose study evaluate safety harmful effect injection BG00001 brain tumor . Also , study help determine whether virus carry beta interferon gene enter brain tumor cell cause cancer cell die . This study require one hospital admission actual procedure drug administration . All visit conduct out-patient basis</brief_summary>
	<brief_title>Dose Escalation Study Determine Safety IFN-Beta Gene Transfer Treatment Grade III &amp; Grade IV Gliomas</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<criteria>1 . Must great equal 18 year age . 2 . Subjects must histologically prove GBM , AA , AMO , malignant astrocytoma NOS gliosarcoma recurrent progressive tumor follow prior treatment . 3 . Tumor must amenable radical resection , resection must clinically indicate . 4 . Must ECOG performance status 02 . 5 . Must anticonvulsant therapy , must therapeutic serum level within 2 week prior Day 1 , therapeutic level define anticonvulsant use . 1 . Abnormal blood test exceed limit define : Alanine transaminase ( ALT ) &gt; four time ( 4X ) upper limit normal ( ULN ) . Aspartate transaminase ( AST ) &gt; 4X ULN . Total bilirubin &gt; 1.5 mg/dL . Absolute neutrophil count &lt; 1,500 cells/mm3 . Platelet count &lt; 100,000 cells/mm3 . Serum creatinine &gt; 2X ULN . Prothrombin time ( PT ) &gt; 2 second ULN . Serum sodium ( Na ) &lt; 125 mEq/L &gt; 150 mEq/L . Serum potassium ( K ) &lt; 3.5 mEq/L &gt; 5.5 mEq/L . 2 . Brainstem , optic chiasm involvement tumor . 3 . Uncontrolled seizure disorder . 4 . History new diagnosis treatment invasive malignancy Grade III Grade IV Glioma within 5 year enrollment . Curatively treated subject history basal cell squamous cell carcinoma skin , superficial transitional cell carcinoma bladder , noninvasive carcinoma uterine cervix exclude . Treatment History : 5 . Treatment radiation therapy , include interstitial radiation radiosurgery , must complete least 8 week prior Day 1 . 6 . Treatment nitrosoureas must complete least 6 week prior Day 1 . Treatment chemotherapeutic agent must complete least 4 week prior Day 1 . 7 . Treatment investigational drug approve therapy investigational use must complete least 4 week prior Day 1 . 8 . History intolerance corticosteroid would preclude use study , history medical condition precludes use corticosteroid . 9 . Any prior treatment gene delivery vector , adenovirus therapeutic . 10 . Women child bear potential must negative serum pregnancy test . 11 . Women postmenopausal , surgically sterile , willing practice effective contraception study . Men surgically sterile willing practice effective contraception study . 12 . Nursing mother , pregnant woman woman plan become pregnant study . 13 . Previous treatment BG00001 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2004</verification_date>
	<keyword>Glioma</keyword>
	<keyword>Brain Tumor</keyword>
	<keyword>Adenovirus</keyword>
	<keyword>Gene Therapy</keyword>
	<keyword>Biogen</keyword>
</DOC>